Insights into Switching Schizophrenia Treatment from Invega Sustenna to UZEDY

Insights into Switching Schizophrenia Treatment

Teva, in partnership with Medincell, presented new data offering valuable insights into transitioning patients with schizophrenia from Invega Sustenna to UZEDY.

Key Findings:

• Benefits: Highlighted potential benefits of switching medications
• Considerations: Discussed key considerations for patients and clinicians

The research adds to the growing body of knowledge surrounding schizophrenia treatment options, emphasizing the importance of individualized care.